SCHEMBL4289287

SCHEMBL4289287

CN1CCN(CC(=O)Nc2ccc3c(c2)C(=O)c2cc(NC(=O)CN4CCN(C)CC4)ccc2C3=O)CC1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TERT O14746 13/20 0.74
ALDH1A1 P00352 2/20 0.61
MAPT P10636 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.56
LMNA P02545 1/20 0.56
GAA P10253 1/20 0.56
ATM Q13315 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
NPC1 O15118 1/20 0.55
CYP1A2 P05177 1/20 0.55
POLB P06746 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
RAB9A P51151 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9630688 1.00 TERT (0.74) TERTALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL21085334 0.89 TERT (0.63) TERTALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL4293444 0.88 TERT (0.95) TERTALDH1A1MAPTLMNA
SCHEMBL4297878 0.87 TERT (0.75) TERTALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL4299285 0.86 TERT (0.76) TERTALDH1A1MAPTSMN1; SMN2GAA
SCHEMBL4291737 0.84 TERT (0.59) TERTALDH1A1MAPT
SCHEMBL9630438 0.84 ALDH1A1 (0.64) TERTALDH1A1SMN1; SMN2LMNAGAA
SCHEMBL9629545 0.81 SMN1; SMN2 (0.65) ALDH1A1MAPTSMN1; SMN2LMNAGAA
SCHEMBL8288400 0.80 LMNA (0.68) ALDH1A1SMN1; SMN2LMNAGAAATM
SCHEMBL31559143 0.79 GAA (0.67) ALDH1A1MAPTSMN1; SMN2LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES TERT, NAT10, POT1 TERT 1/4885ALDH1A1 481/4885MAPT 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.